Conference Coverage

Intranasal naloxone promising for type 1 hypoglycemia


 

REPORTING FROM ADA 2018

The study subjects were men, 43 years old, on average, with a mean body mass index of 26 kg/m2.

The investigators didn’t have any disclosures, and there was no industry funding for the work.

SOURCE: Aleksic S et al. ADA 2018, Abstract 10-LB.

Pages

Recommended Reading

Diabetes risk may rise with work hours
MDedge Family Medicine
CANVAS program analysis: Canagliflozin benefits patients with T2DM and poor kidney function
MDedge Family Medicine
Chronic kidney disease is 40% more common in T2DM than T1DM
MDedge Family Medicine
Study spotlights risk factors for albuminuria in youth with T2DM
MDedge Family Medicine
Uric acid tied to pediatric diabetic kidney disease
MDedge Family Medicine
CANVAS data: Canagliflozin generally well tolerated up to 6.5 years
MDedge Family Medicine
RISE: Insulin glargine, metformin offer no beta cell function benefit in youth
MDedge Family Medicine
Fluoroquinolones can cause fatal hypoglycemia, FDA warns
MDedge Family Medicine
Meet the rare diabetes diagnosis that thrills patients
MDedge Family Medicine
Special care advised for HIV-infected patients with diabetes
MDedge Family Medicine